The clinical trial is evaluating two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome, which has a 5% to 15% fatality rate and affects tens of thousands of people annually. Currently no vaccine is available.
PharmaJet's delivery device was chosen for this Phase 1 trial after pre-clinical studies with similar vaccines showed significantly higher (tenfold increase) immunogenicity with the needle-free device, as compared to needle and syringe, and comparable results to electroporation.
PharmaJet's mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market.
The PharmaJet Needle-free Injectors are safe, fast and easy-to-use. They eliminate needle stick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine